Company intelligence / Profile preview

GTP Bioways

Ownership: Private
Development stage: Commercial

Overview

GTP Bioways is a leading French-based biologics CDMO with over 20 years of experience. It specializes in process development and GMP manufacturing of biologics, bioconjugates (including ADCs), proteins, enzymes, nanodrugs, and offers fill & finish services. The company operates four sites in France with expertise spanning from R&D to commercial supply. In July 2024 it was acquired by Olon Group.

Modalities: Monoclonal antibodyAntibody-drug conjugateProteinEnzyme replacement therapyRecombinant proteinNanoparticle (nanodrug)
Industry: Contract Manufacturing Organization

Partnerships

Olon Group (parent/strategic integration)Other partnerships are project-based with biopharma companies but not specifically named.

Beyond the preview

Go deeper on GTP Bioways.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTP Bioways.